Tenon Medical, Inc.
For the period ended Dec 31, 2024. Filed Mar 26, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 26, 2025
TNON$1.75+6.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
(In thousands, except share data)
| December 31, | December 31, | |
|---|---|---|
| 2024 | 2023 | |
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $6,535 | $2,428 |
| Accounts receivable, net | 863 | 518 |
| Inventory, net | 606 | 554 |
| Prepaid expenses and other current assets | 206 | 389 |
| Total current assets | 8,210 | 3,889 |
| Property and equipment, net | 752 | 961 |
| Deposits | 51 | 51 |
| Operating lease right-of-use asset | 399 | 646 |
| Deferred offering costs | 431 | 798 |
| TOTAL ASSETS | $9,843 | $6,345 |
| Liabilities and Stockholders’ EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $369 | $433 |
| Accrued expenses | 910 | 808 |
| Current portion of accrued commissions | 303 | 470 |
| Current portion of operating lease liability | 287 | 256 |
| Convertible notes payable and accrued interest, net of debt discount of $0 and $77 at December 31, 2024 and 2023, respectively | — | 1,173 |
| Total current liabilities | 1,869 | 3,140 |
| Accrued commissions, net of current portion | 1,862 | 1,999 |
| Operating lease liability, net of current portion | 141 | 428 |
| Total liabilities | 3,872 | 5,567 |
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Series A convertible preferred stock, $0.001 par value; 4,500,000 shares authorized at December 31, 2024 and 2023; 256,968 and 0 shares issued and outstanding at December 31, 2024 and 2023, respectively | 3,300 | — |
| Series B convertible preferred stock, $0.001 par value; 491,222 shares authorized at December 31, 2024 and 2023; 86,454 and 0 shares issued and outstanding at December 31, 2024 and 2023, respectively | 452 | — |
| Common stock, $0.001 par value; 130,000,000 shares authorized at December 31, 2024 and 2023; 3,138,804 and 325,039 shares issued and outstanding at December 31, 2024 and 2023, respectively | 3 | — |
| Additional paid-in capital | 70,962 | 55,897 |
| Accumulated deficit | (68,746) | (55,073) |
| Accumulated other comprehensive loss | — | (46) |
| Total stockholders’ equity | 5,971 | 778 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $9,843 | $6,345 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.